COM:ALLOGENE
Allogene Therapeutics, Inc.
- Stock
Last Close
2.11
22/11 21:00
Market Cap
498.99M
Beta: -
Volume Today
1.42M
Avg: -
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|
average inventory | -130.98M - | -161.35M 23.18% | -30.36M 81.18% | -31.23M - | ||||
average payables | 6.17M - | 10.79M 74.97% | 9.82M 9.02% | 10.32M 5.12% | 12.07M 16.95% | 9.89M 18.05% | ||
average receivables | 1.55M - | 2.76M 77.32% | 1.20M 56.40% | 1.65M - | ||||
book value per share | 24.29 - | 6.22 74.38% | 8.97 44.10% | 6.75 24.77% | 4.65 31.06% | 0.00 99.93% | ||
capex per share | -0.11 - | -0.50 349.87% | -0.55 9.03% | -0.16 71.18% | -0.04 77.03% | -0.00 99.97% | ||
capex to depreciation | -2.16 - | -10.10 368.63% | -8.69 13.94% | -2.05 76.41% | -0.36 82.30% | -0.11 70.60% | ||
capex to operating cash flow | 0.07 - | 0.37 410.59% | 0.57 54.97% | 0.12 79.75% | 0.02 79.71% | 0.01 72.91% | ||
capex to revenue | -0.56 - | -21.36 3,733.85% | -15.96 25.30% | |||||
cash per share | 37.59 - | 9.34 75.15% | 13.93 49.08% | 8.05 42.20% | 7.21 10.46% | 0.00 99.96% | ||
days of inventory on hand | ||||||||
days payables outstanding | ||||||||
days sales outstanding | ||||||||
debt to assets | 0.04 - | 0.07 60.67% | 0.04 38.77% | 0.07 53.70% | 0.12 83.82% | 0.14 11.04% | ||
debt to equity | 0.05 - | 0.08 66.59% | 0.05 38.97% | 0.08 53.18% | 0.15 99.02% | 0.17 13.57% | ||
dividend yield | ||||||||
earnings yield | -0.27 - | -0.07 74.09% | -0.08 9.30% | -0.12 57.22% | -0.37 203.18% | -0.00 99.82% | ||
enterprise value | 92.69M - | 2.09B 2,152.83% | 2.06B 1.35% | 1.29B 37.52% | 419.05M 67.44% | 503.76B 120,114.82% | ||
enterprise value over ebitda | -0.45 - | -11.29 2,437.16% | -7.98 29.36% | -5.03 36.93% | -1.25 75.17% | -1.54K 122,943.60% | ||
ev to operating cash flow | -2.08 - | -15.20 632.40% | -17.90 17.72% | -6.96 61.09% | -1.90 72.71% | -2.12K 111,410.19% | ||
ev to sales | 33.44 - | 1.72K 5,057.65% | 5.30M 307,396.86% | |||||
free cash flow per share | -1.65 - | -1.86 12.54% | -1.50 19.21% | -1.52 0.96% | -1.58 3.83% | -0.00 99.90% | ||
free cash flow yield | -0.06 - | -0.07 16.65% | -0.06 16.84% | -0.10 70.80% | -0.25 146.29% | -0.00 99.81% | ||
graham net net | 30.71 - | 8.18 73.35% | 12.70 55.19% | 7.15 43.68% | 6.15 13.97% | 0.00 99.97% | ||
graham number | 63.19 - | 15.99 74.69% | 19.78 23.70% | 16.54 16.38% | 15.53 6.13% | 0.01 99.92% | ||
income quality | 0.21 - | 0.74 252.44% | 0.46 38.18% | 0.72 56.34% | 0.66 7.81% | 0.73 9.57% | ||
intangibles to total assets | 0 - | 0.00 Infinity% | 0.00 78.41% | 0 100% | 0 | 0 | 0 | |
interest coverage | -57.43 - | 19.60 - | ||||||
interest debt per share | 1.31 - | 0.51 61.10% | 0.45 12.06% | 0.51 15.23% | 0.59 13.99% | 0.00 99.90% | ||
inventory turnover | ||||||||
invested capital | 0.05 - | 0.08 66.59% | 0.05 38.97% | 0.08 53.18% | 0.15 99.02% | 0.17 13.57% | ||
market cap | 779.58M - | 2.63B 236.79% | 3.04B 15.71% | 2.03B 33.30% | 900.40M 55.57% | 503.75B 55,847.74% | ||
net current asset value | -2K - | 397.29M 19,864,650% | 455.80M 14.73% | 696.92M 52.90% | 687.25M 1.39% | 377.62M 45.05% | 328.51M 13.00% | |
net debt to ebitda | 3.30 - | 2.91 11.87% | 3.79 30.34% | 2.89 23.68% | 1.43 50.37% | -0.02 101.10% | ||
net income per share | -7.31 - | -1.83 75.00% | -1.94 6.19% | -1.80 7.06% | -2.30 27.81% | -0.00 99.91% | ||
operating cash flow per share | -1.54 - | -1.36 11.89% | -0.96 29.65% | -1.36 42.31% | -1.54 13.21% | -0.00 99.90% | ||
payables turnover | ||||||||
receivables turnover | ||||||||
research and ddevelopement to revenue | 5.72 - | 1.06K 18,344.05% | 2.56K 142.35% | |||||
return on tangible assets | -0.27 - | -0.26 5.98% | -0.19 26.08% | -0.24 23.97% | -0.40 71.23% | -0.51 26.12% | ||
revenue per share | 0.28 - | 0.00 99.40% | 0.00 99.96% | |||||
roe | -0.30 - | -0.29 2.44% | -0.22 26.31% | -0.27 23.55% | -0.50 85.39% | -0.64 28.99% | ||
roic | -0.25 - | -0.28 10.39% | -0.20 26.35% | -0.23 13.67% | -0.39 67.23% | -0.48 23.31% | ||
sales general and administrative to revenue | 1.93 - | 326.36 16,850.54% | 754.45 131.17% | |||||
shareholders equity per share | 24.29 - | 6.22 74.38% | 8.97 44.10% | 6.75 24.77% | 4.65 31.06% | 0.00 99.93% | ||
stock based compensation to revenue | 2.10 - | 344.03 16,284.32% | 694.22 101.79% | |||||
tangible asset value | -2K - | 702.41M 35,120,600% | 628.87M 10.47% | 1.08B 71.68% | 916.41M 15.12% | 665.87M 27.34% | 512.23M 23.07% | |
tangible book value per share | 24.26 - | 6.22 74.35% | 8.97 44.14% | 6.75 24.77% | 4.65 31.06% | 0.00 99.93% | ||
working capital | -2K - | 438.52M 21,926,250% | 511.50M 16.64% | 750.81M 46.79% | 761.31M 1.40% | 474.31M 37.70% | 422.04M 11.02% |
All numbers in USD (except ratios and percentages)